Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...

Headlines,Regeneron Pharmaceuticals' shares fell by 4.63% following a court ruling.,The decision involved a legal dispute ...

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ: REGN) shares are down a further 4% Tuesday, with analysts turning more ...